Table 2. Multivariable analysis for survival after diagnosis of metastatic breast cancer.

	All patients			Patients without (neo)adjuvant systemic therapy
	n =815			n=318
	Hazard ratio	95% CI	P-value	Hazard Ratio	95% CI	P-value
Recurrent with MFI <24 months vs de novo	1.97	1.49–2.60	<0.0001	1.69	1.11–2.58	0.015
Recurrent with MFI >24 months vs de novo	0.89	0.70–1.14	0.358	0.89	0.64–1.24	0.498
Age at diagnosis of metastatic breast cancer	1.02	1.01–1.02	<0.0001	1.02	1.00–1.03	0.008
Hormone receptor negative vs positive	1.74	1.40–2.17	<0.0001	2.21	1.58–3.11	<0.0001
HER2 negative vs positive	1.44	1.13–1.83	0.003	1.27	0.88–1.86	0.207
Visceral metastases as initial metastatic site vs bone	1.80	1.41–2.31	<0.0001	1.56	1.03–2.36	0.037
Brain metastases as initial metastatic site vs bone	2.31	1.40–3.80	0.001	4.50	1.49–13.64	0.008
Skin/lymph nodes as initial metastatic site vs bone	1.06	0.71–1.59	0.783	1.37	0.71–2.67	0.350
Multiple initial metastatic sites vs 1 metastatic site	2.30	1.81–2.93	<0.0001	2.66	1.83–3.87	<0.0001

Abbreviations: CI=confidence interval; MFI=metastatic-free interval.